kwic
treatment
treatment
right
on
off
323
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for treatment out of >500 occurrences
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
[frequency of next (right) word to treatment]
677804 occurrences (No.8 in the rank) during 5 years in the PubMed. [cache]
| 323) physiology, pathophysiology, and disease treatment as they relate to gynecologic ma |
| 324) mbiont-free strain obtained by antibiotic treatment as well as genome analyses revea |
| 325) rofile followed by 2 weeks of either Epi treatment at 1 mg/kg/day by gavage (n = |
| 326) veloped for evaluating only one candidate treatment at a time, and are thus not opti |
| 327) he Bayesian posterior probability of each treatment being optimal. |
| 328) HNC) are diagnosed worldwide with primary treatment being surgery and radiotherapy. |
| 329) The average difference in post-treatment compared to pre-treatment non-HD |
| 330) high Drug Burden Index (DBI) polypharmacy treatment compared to control on physical |
| 331) on administration, hygiene and isolation, treatment decisions, or invasive procedure |
| 332) To improve dengue triage and treatment decisions, the WHO recommends cl |
| 333) aying reward responsiveness to accelerate treatment development for neuropsychiatric |
| 334) ions and laboratory animals, which hamper treatment development. |
| 335) Moreover, statin treatment did not reduce the number of flo |
| 336) Importantly, statin treatment did not reverse d-flow-regulated |
| 337) Treatment dose (amount of treatment) has b |
| 338) or post-stroke aphasia and to explore how treatment dose is conceptualized, measured |
| 339) approach to alleviate liver fibrosis, and treatment efficacy can be monitored by obs |
| 340) ould very likely be necessary to maintain treatment efficacy. |
| 341) The use of specific clinical treatment goals (e.g., two-hour pain free |
| 342) iol doses ≥ 1.5 mcg/day to meet current treatment goals. |
| 343) ificant main effect in the high vitamin D treatment group in VDAART. |
| 344) Studies were included if they had a treatment group with a mean age of 65 year |
| 345) ties are different or the sample sizes of treatment groups are unbalanced. |
| 346) ion of unbalanced sample sizes in the two treatment groups or large treatment effect |
| 347) entlessly for the single most efficacious treatment may indirectly diminish the numb |
| 348) lts suggest that long-term PARP inhibitor treatment may prime both BRCA1 mutant and |
| 349) is that readers may focus overly on what treatment ranks best and focus insufficien |
| 350) or to compare the intervals or ranges of treatment ranks. |
| 351) Mechanistically, adropin treatment reduced BBB damage, degradation |
| 352) No studies showed that antifungal treatment reduced mortality. |
| 353) m regulator of cell fate, plasticity, and treatment resistance in NEPC that can rev |
| 354) etect rare subclones possibly involved in treatment resistance. |
| 355) tential to help in prevention, diagnosis, treatment, screening, management, and cont |
[
right
kwic]
(1)68  of |
(13)7 planning |
(25)3 outcome |
(37)2 efficacy |
| (2)50 *null* | (14)6 to |
(26)3 protocols |
(38)2 goals |
| (3)29 and |
(15)4 approaches |
(27)3 that |
(39)2 group |
| (4)23 for |
(16)4 methods |
(28)2 a |
(40)2 groups |
| (5)22 with |
(17)4 option |
(29)2 as |
(41)2 may |
| (6)15 options |
(18)4 options, |
(30)2 at |
(42)2 ranks |
| (7)13 in |
(19)4 ranking |
(31)2 being |
(43)2 reduced |
| (8)9 effect |
(20)4 regimens |
(32)2 compared |
(44)2 resistance |
| (9)9 effects |
(21)4 strategies |
(33)2 decisions, |
(45)2 screening, |
| (10)8 is |
(22)3 adherence |
(34)2 development |
(46)2 through |
| (11)8 on |
(23)3 approach |
(35)2 did |
(47)2 were |
| (12)7 outcomes |
(24)3 or |
(36)2 dose |
add keyword
--- WordNet output for treatment ---